1. Home
  2. HOWL vs VTGN Comparison

HOWL vs VTGN Comparison

Compare HOWL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • VTGN
  • Stock Information
  • Founded
  • HOWL 2017
  • VTGN 1998
  • Country
  • HOWL United States
  • VTGN United States
  • Employees
  • HOWL N/A
  • VTGN N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • VTGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • VTGN Health Care
  • Exchange
  • HOWL Nasdaq
  • VTGN Nasdaq
  • Market Cap
  • HOWL 87.4M
  • VTGN 82.7M
  • IPO Year
  • HOWL 2021
  • VTGN N/A
  • Fundamental
  • Price
  • HOWL $1.36
  • VTGN $2.81
  • Analyst Decision
  • HOWL Strong Buy
  • VTGN
  • Analyst Count
  • HOWL 2
  • VTGN 0
  • Target Price
  • HOWL $9.50
  • VTGN N/A
  • AVG Volume (30 Days)
  • HOWL 263.3K
  • VTGN 185.2K
  • Earning Date
  • HOWL 03-06-2025
  • VTGN 02-13-2025
  • Dividend Yield
  • HOWL N/A
  • VTGN N/A
  • EPS Growth
  • HOWL N/A
  • VTGN N/A
  • EPS
  • HOWL N/A
  • VTGN N/A
  • Revenue
  • HOWL $3,386,000.00
  • VTGN $876,000.00
  • Revenue This Year
  • HOWL N/A
  • VTGN N/A
  • Revenue Next Year
  • HOWL $34.17
  • VTGN N/A
  • P/E Ratio
  • HOWL N/A
  • VTGN N/A
  • Revenue Growth
  • HOWL N/A
  • VTGN 8.08
  • 52 Week Low
  • HOWL $1.26
  • VTGN $2.22
  • 52 Week High
  • HOWL $8.19
  • VTGN $5.74
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 41.40
  • VTGN 45.62
  • Support Level
  • HOWL $1.26
  • VTGN $2.81
  • Resistance Level
  • HOWL $1.45
  • VTGN $3.04
  • Average True Range (ATR)
  • HOWL 0.09
  • VTGN 0.16
  • MACD
  • HOWL 0.02
  • VTGN -0.02
  • Stochastic Oscillator
  • HOWL 45.45
  • VTGN 27.03

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: